Hemophilia B Treatment Market Surges with 7.6% CAGR, set to Hit $8.97 Billion by 2034 | Fact.MR Report
25. November 2024 07:30 ET
|
FACT.MR
Rockville, MD, Nov. 25, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Hemophilia B treatment market is estimated to reach a...
Patient Chart Audit Reveals Changing Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Dynamics As New Competition Challenges Alexion/Astra Zeneca's Soliris and Ultomiris
21. November 2024 09:27 ET
|
Spherix Global Insights
EXTON, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its first annual chart audit study in hematology, Patient Chart Dynamix™ : Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
14. Oktober 2024 12:33 ET
|
Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran
27. März 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 27, 2024 (GLOBE NEWSWIRE) -- Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009,...
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
20. Juni 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
15. Mai 2023 07:05 ET
|
uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
30. März 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the commercial payment and a portion of the milestone rights to IXINITY®...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
23. Februar 2023 08:05 ET
|
uniQure Inc.
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
21. Februar 2023 07:05 ET
|
uniQure Inc.
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
16. Dezember 2022 07:15 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...